Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Advanced Research on Nanomaterials for Regenerative Medicine
share announcement

Advanced Research on Nanomaterials for Regenerative Medicine

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Nanomedicine and Nanobiology".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 3470

Special Issue Editor

Dr. Eleni Papachristou

E-Mail Website
Guest Editor
Laboratory of Biochemistry, School of Chemistry, Faculty of Sciences, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece
Interests: mesenchymal stem cell therapy; apoptosis; differentiation; biomaterials; cell cycle; cancer; mRNA therapeutics

Special Issue Information

Dear Colleagues,

The Special Issue “Advanced Research on Nanomaterials for Regenerative Medicine” will focus on using nano-biomaterials for the treatment of degenerative disorders.

Nowadays, the development of biomaterials has entered the “nanotechnology era”. A modern approach in the treatment of degenerative diseases includes the nanotechnology-based mesenchymal stem cell therapy, encapsulation of pharmacophores in nanomaterials and drug delivery systems, tissue engineering and the use of “intelligent nanobiomaterials” for delivering bioactive signals for tissue regeneration. Within this Special Issue, we will discuss current advances in nano/biomaterials research, tissue engineering applications, drug delivery systems, nanotechnology-based disease detection systems, and development of therapeutic approaches using “intelligent nano or biomaterials”. The main requirement that such materials should fulfil is biocompatibility and the potential to serve as “signal transducers” to mesenchymal stem cells for regenerative purposes.

This Special Issue is open for the submission of basic and clinical research, or that taking a multi-disciplinary approach, and will also cover original articles and reviews on the following topics:

  • Novel therapeutic approaches including biomaterials.
  • Drug delivery systems.
  • Nanotechnology-based mesenchymal stem cell therapy.
  • Bioactive signals delivery for mesenchymal stem cell differentiation.
  • Application of nano materials in osteogenesis, chondrogenesis, angiogenesis, neurogenesis, etc.
  • Clinical trials/research on nanobiomaterials.
  • Tissue engineering.

Dr. Eleni Papachristou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • intelligent nanobiomaterials
  • regenerative medicine
  • drug delivery
  • tissue engineering
  • cell differentiation
  • clinical applications
  • mesenchymal stem cell therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 3720 KiB  
Article
Advancing Nanoscale Science: Synthesis and Bioprinting of Zeolitic Imidazole Framework-8 for Enhanced Anti-Infectious Therapeutic Efficacies
by Muhammad Saqib Saif, Murtaza Hasan, Ayesha Zafar, Muhammad Mahmood Ahmed, Tuba Tariq, Muhammad Waqas, Riaz Hussain, Amna Zafar, Huang Xue and Xugang Shu
Biomedicines 2023, 11(10), 2832; https://doi.org/10.3390/biomedicines11102832 - 18 Oct 2023
Cited by 3 | Viewed by 1149
Abstract
Bacterial infectious disorders are becoming a major health problem for public health. The zeolitic imidazole framework-8 with a novel Cordia myxa extract-based (CME@ZIF-8) nanocomposite showed variable functionality, high porosity, and bacteria-killing activity against Staphylococcus aureus, and Escherichia coli strains have been created by [...] Read more.
Bacterial infectious disorders are becoming a major health problem for public health. The zeolitic imidazole framework-8 with a novel Cordia myxa extract-based (CME@ZIF-8) nanocomposite showed variable functionality, high porosity, and bacteria-killing activity against Staphylococcus aureus, and Escherichia coli strains have been created by using a straightforward approach. The sizes of synthesized zeolitic imidazole framework-8 (ZIF-8) and CME@ZIF-8 were 11.38 nm and 12.44 nm, respectively. Prepared metal organic frameworks have been characterized by gas chromatography–mass spectroscopy, Fourier transform spectroscopy, UV–visible spectroscopy, X-ray diffraction, scanning electron microscopy, and energy-dispersive X-ray spectroscopy. An antibacterial potential comparison between CME@ZIF-8 and zeolitic imidazole framework-8 has shown that CME@ZIF-8 was 31.3%, 28.57%, 46%, and 47% more efficient than ZIF-8 against Staphylococcus aureus and 43.7%, 42.8%, 35.7%, and 70% more efficient against Escherichia coli, while it was 31.25%, 33.3%, 46%, and 46% more efficient than the commercially available ciprofloxacin drug against Staphylococcus aureus and 43.7%, 42.8%, 35.7%, and 70% more efficient against Escherichia coli, respectively, for 750, 500, 250, and 125 μg mL−1. Minimum inhibitory concentration values of CME@ZIF-8 for Escherichia coli and Staphylococcus aureus were 15.6 and 31.25 μg/mL respectively, while the value of zeolitic imidazole framework-8 alone was 62.5 μg/mL for both Escherichia coli and Staphylococcus aureus. The reactive oxygen species generated by CME@ZIF-8 destroys the bacterial cell and its organelles. Consequently, the CME@ZIF-8 nanocomposites have endless potential applications for treating infectious diseases. Full article
(This article belongs to the Special Issue Advanced Research on Nanomaterials for Regenerative Medicine)
►▼ Show Figures

Graphical abstract

27 pages, 7042 KiB  
Article
Fabrication of a Smart Fibrous Biomaterial That Harbors an Active TGF-β1 Peptide: A Promising Approach for Cartilage Regeneration
by Aglaia Mantsou, Eleni Papachristou, Panagiotis Keramidas, Paraskevas Lamprou, Maria Pitou, Rigini M. Papi, Katerina Dimitriou, Amalia Aggeli and Theodora Choli-Papadopoulou
Biomedicines 2023, 11(7), 1890; https://doi.org/10.3390/biomedicines11071890 - 03 Jul 2023
Cited by 1 | Viewed by 1357
Abstract
The regeneration of articular cartilage remains a serious problem in various pathological conditions such as osteoarthritis, due to the tissue’s low self-healing capacity. The latest therapeutic approaches focus on the construction of biomaterials that induce cartilage repair. This research describes the design, synthesis, [...] Read more.
The regeneration of articular cartilage remains a serious problem in various pathological conditions such as osteoarthritis, due to the tissue’s low self-healing capacity. The latest therapeutic approaches focus on the construction of biomaterials that induce cartilage repair. This research describes the design, synthesis, and investigation of a safe, “smart”, fibrous scaffold containing a genetically incorporated active peptide for chondrogenic induction. While possessing specific sequences and the respective mechanical properties from natural fibrous proteins, the fibers also incorporate a Transforming Growth Factor-β1 (TGF-β1)-derived peptide (YYVGRKPK) that can promote chondrogenesis. The scaffold formed stable porous networks with shear-thinning properties at 37 °C, as shown by SEM imaging and rheological characterization, and were proven to be non-toxic to human dental pulp stem cells (hDPSCs). Its chondrogenic capacity was evidenced by a strong increase in the expression of specific chondrogenesis gene markers SOX9, COL2, ACAN, TGFBR1A, and TGFBR2 in cells cultured on “scaffold-TGFβ1” for 21 days and by increased phosphorylation of intracellular signaling proteins Smad-2 and Erk-1/2. Additionally, intense staining of glycosaminoglycans was observed in these cells. According to our results, “scaffold-TGFβ1” is proposed for clinical studies as a safe, injectable treatment for cartilage degeneration. Full article
(This article belongs to the Special Issue Advanced Research on Nanomaterials for Regenerative Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop